Eam Investors, LLC Rigel Pharmaceuticals Inc Transaction History

Eam Investors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 14, 2018	SELL	$3.54 - $4.54 $791,696 - $1.02 Million	-223,643 Closed	0 $0
Q4 2017 May 21, 2018	SELL	$3.23 - $4.3 $813,863 - $1.08 Million	-251,970 Reduced 52.98%	223,643 $868,000
Q4 2017 Feb 12, 2018	BUY	$3.23 - $4.3 $1.54 Million - $2.05 Million	475,613	475,613 $1.85 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.